Vendor, San Carlos, CA
Gencyte Therapeutics Inc.
UEI KLLTVAECBMN8, CAGE 7ZVP4
2 awards and $499,990 obligated between February 26, 2024 and July 16, 2026, 100% under full and open competition, against 16.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $499,990 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 1 |
| Small Business Set Aside - Partial | 1 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00046Definitive Contract, September 3, 2025, Full and Open Competition After Exclusion of Sources, 16 offers | NIH NCINational Institutes of Health | Phase I SBIR Concept Award for Logic Gated Molecular Adaptor System for JMML TreatmentNAICS 541715, PSC AN12 | $499,990 |
| 75N91023C00014Definitive Contract, February 26, 2024, Full and Open Competition After Exclusion of Sources, 17 offers | NIH NCINational Institutes of Health | The Purpose of This Modification Is to Extend the Period of Performance from February 26, 2024 to August 26, 2024NAICS 541715, PSC AN12 | $0 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 5 across 2 awards